Allos Therapeutics (NASDAQ: ALTH) announced positive interim data from their Phase I dose optimization study of PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The data demonstrated activity in a range of doses, and will continue with the objective of determining the optimal dose [...]